An analysis of FDA-approved drugs for oncology

Drug Discovery Today

Volumn 19, Issue 12, 2014, Pages 1831-1835

  Kinch, Michael S ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; NEW DRUG; ORPHAN DRUG; PROTEIN KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER RESEARCH; DRUG APPROVAL; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; SCHOOL; INDUSTRY; NEOPLASMS; UNITED STATES; UNIVERSITY;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; INDUSTRY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UNIVERSITIES;

EID: 84919395951     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.007     Document Type: Short Survey

References (21)

1. R. Rettig Cancer Crusade: The Story of the National Cancer Act of 1971 2005 iUniverse
2. J.C. Dacre, and M. Goldman Toxicology and pharmacology of the chemical warfare agent sulfur mustard Pharmacol. Rev. 48 1996 289 326
3. A. Gilman The initial clinical trial of nitrogen mustard Am. J. Surg. 105 1963 574 578
4. G.B. Infield Disaster at Bari 1974 Hale
5. J. Hirsch An anniversary for cancer chemotherapy JAMA 296 2006 1518 1520
6. R.J. Papac Origins of cancer therapy Yale J. Biol. Med. 74 2001 391
7. L.S. Goodman Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders JAMA 251 1946 2255 2261
8. R.L. Schilsky A concise history of the cancer and leukemia group B Clin. Cancer Res. 12 2006 3553s 3555s
9. D.R. Miller A tribute to Sidney Farber - the father of modern chemotherapy Br. J. Haematol. 134 2006 20 26
10. E.J. Freireich The history of leukemia therapy - a personal journey Clin. Lymphoma Myeloma Leuk. 12 2012 386 392
11. D.G. Pfister Off-label use of oncology drugs: the need for more data and then some J. Clin. Oncol. 30 2012 584 586
12. C. Downs The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy AJHP 64 2007 S13 S15 quiz S21-23
13. M. Soares "Off-label" indications for oncology drug use and drug compendia: history and current status J. Oncol. Pract. 1 2005 102 105
14. D.C. Mowery The growth of patenting and licensing by US universities: an assessment of the effects of the Bayh-Dole act of 1980 Res. Policy 30 2001 99 119
15. G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934
16. A. Ullrich, and J. Schlessinger Signal transduction by receptors with tyrosine kinase activity Cell 61 1990 203 212
17. M.S. Kinch, and E. Patridge An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs Drug Discov. Today 2014 10.1016/j.drudis.2014.05.012
18. E.A. Richey Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J. Clin. Oncol. 27 2009 4398 4405
19. O. Wellman-Labadie, and Y. Zhou The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95 2010 216 228
20. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
21. B.A. Muller Imatinib and its successors - how modern chemistry has changed drug development Curr. Pharm. Des. 15 2009 120 133